top of page

July 2023 // Communication

Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking new findings on an endocannabinoid transporter at the 10th Gordon Research Conference - Monday the 17th 2023 at 07h00 PM.

Prof. Jürg Gertsch, provided for the first time new insights into the novel transport mechanism that influences the balance of the endocannabinoid system, identifying and characterising the biological machinery responsible for endocannabinoid cell reuptake.

Synendos investigates the therapeutic potential of this novel mode of action and Prof. Gertsch's pioneering research forms the basis of Synendos’ approach.

Read more details in the article:

Recent Posts

See All

January 2024 // Company & Communication

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510. Synendos transitions to a clinical-stage biotech company developing innovative Endocanna

September 2022 // Company & Communication

Synendos Therapeutics is ranked TOP 100 Swiss Startups 2022 We are honored to be listed for the second year in a row as one of the TOP 100 Swiss Startups 2022. A big thank you to our team, partners, c


bottom of page